Selected research
Industry Research
Viral Vaccines Industry Research Report 2026
Market perspective
The global Viral Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Viral Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Viral Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Viral Vaccines include GSK, Sanofi, Novartis, Merck, Pfizer, Bayer, Zoetis, Johnson and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Viral Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (W Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Viral Vaccines Market by Company
GSK
Sanofi
Novartis
Merck
Pfizer
Bayer
Zoetis
Johnson
CSL
AstraZeneca
Viral Vaccines Segment by Type
Attenuated Vaccine
Inactivated Vaccine
Viral Vaccines Segment by Application
Research Institute
Hospital
Pharmaceutical Factory
Others
Viral Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Viral Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Viral Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Viral Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Attenuated Vaccine
- Inactivated Vaccine
Applications
- Research Institute
- Hospital
- Pharmaceutical Factory
- Others
Companies covered
- GSK
- Sanofi
- Novartis
- Merck
- Pfizer
- Bayer
- Zoetis
- Johnson
- CSL
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Viral Vaccines Market Size (2021-2032)
- 2.2.2 Global Viral Vaccines Sales (2021-2032)
- 2.2.3 Global Viral Vaccines Market Average Price (2021-2032)
- 2.3 Viral Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Attenuated Vaccine
- 2.3.3 Inactivated Vaccine
- 2.4 Viral Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Research Institute
- 2.4.3 Hospital
- 2.4.4 Pharmaceutical Factory
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Viral Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Viral Vaccines Sales (W Tons) of Manufacturers (2021-2026)
- 3.3 Global Viral Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Viral Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Viral Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Viral Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Viral Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Viral Vaccines, Established Date
- 3.9 Global Viral Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Viral Vaccines Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Viral Vaccines Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Viral Vaccines Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Viral Vaccines Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Viral Vaccines Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Viral Vaccines Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Zoetis
- 4.7.1 Zoetis Company Information
- 4.7.2 Zoetis Business Overview
- 4.7.3 Zoetis Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zoetis Viral Vaccines Product Portfolio
- 4.7.5 Zoetis Recent Developments
- 4.8 Johnson
- 4.8.1 Johnson Company Information
- 4.8.2 Johnson Business Overview
- 4.8.3 Johnson Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Johnson Viral Vaccines Product Portfolio
- 4.8.5 Johnson Recent Developments
- 4.9 CSL
- 4.9.1 CSL Company Information
- 4.9.2 CSL Business Overview
- 4.9.3 CSL Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSL Viral Vaccines Product Portfolio
- 4.9.5 CSL Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Viral Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Viral Vaccines Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
5 Global Viral Vaccines Market Scenario by Region
- 5.1 Global Viral Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Viral Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Viral Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Viral Vaccines Sales by Region: 2027-2032
- 5.3 Global Viral Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Viral Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Viral Vaccines Revenue by Region: 2027-2032
- 5.4 North America Viral Vaccines Market Facts & Figures by Country
- 5.4.1 North America Viral Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Viral Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Viral Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Viral Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Viral Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Viral Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Viral Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Viral Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Viral Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Viral Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Viral Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Viral Vaccines Market Facts & Figures by Country
- 5.7.1 South America Viral Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Viral Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Viral Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Viral Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Viral Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Viral Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Viral Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Viral Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Viral Vaccines Sales by Type (2021-2032) & (W Tons)
- 6.1.2 Global Viral Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Viral Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Viral Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Viral Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Viral Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Viral Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Viral Vaccines Sales by Application (2021-2032) & (W Tons)
- 7.1.2 Global Viral Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Viral Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Viral Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Viral Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Viral Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Viral Vaccines Value Chain Analysis
- 8.1.1 Viral Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Viral Vaccines Production Mode & Process
- 8.2 Viral Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Viral Vaccines Distributors
- 8.2.3 Viral Vaccines Customers
9 Global Viral Vaccines Analyzing Market Dynamics
- 9.1 Viral Vaccines Industry Trends
- 9.2 Viral Vaccines Industry Drivers
- 9.3 Viral Vaccines Industry Opportunities and Challenges
- 9.4 Viral Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst